CA2733775A1 - Agent for promoting neuronal differentiation and method therefor - Google Patents
Agent for promoting neuronal differentiation and method therefor Download PDFInfo
- Publication number
- CA2733775A1 CA2733775A1 CA2733775A CA2733775A CA2733775A1 CA 2733775 A1 CA2733775 A1 CA 2733775A1 CA 2733775 A CA2733775 A CA 2733775A CA 2733775 A CA2733775 A CA 2733775A CA 2733775 A1 CA2733775 A1 CA 2733775A1
- Authority
- CA
- Canada
- Prior art keywords
- coup
- protein
- inhibitor
- cells
- neurons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004031 neuronal differentiation Effects 0.000 title claims abstract description 22
- 230000001737 promoting effect Effects 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title description 22
- 102000013014 COUP Transcription Factor I Human genes 0.000 claims abstract description 37
- 108010065376 COUP Transcription Factor I Proteins 0.000 claims abstract description 37
- 102000008523 COUP Transcription Factor II Human genes 0.000 claims abstract description 36
- 108010020650 COUP Transcription Factor II Proteins 0.000 claims abstract description 36
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 210000000130 stem cell Anatomy 0.000 claims abstract description 13
- 210000001178 neural stem cell Anatomy 0.000 claims abstract description 11
- 210000002569 neuron Anatomy 0.000 claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 31
- 239000004055 small Interfering RNA Substances 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 230000004568 DNA-binding Effects 0.000 claims description 16
- 230000006957 competitive inhibition Effects 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 238000013518 transcription Methods 0.000 claims description 13
- 230000035897 transcription Effects 0.000 claims description 13
- 210000001222 gaba-ergic neuron Anatomy 0.000 claims description 12
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 claims description 11
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 claims description 11
- 210000002932 cholinergic neuron Anatomy 0.000 claims description 11
- 102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 claims description 9
- 108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 108020004459 Small interfering RNA Proteins 0.000 claims description 7
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 7
- 210000001362 glutamatergic neuron Anatomy 0.000 claims description 7
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 61
- 102000004101 COUP Transcription Factors Human genes 0.000 description 31
- 108010043071 COUP Transcription Factors Proteins 0.000 description 31
- 230000004069 differentiation Effects 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000713666 Lentivirus Species 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 210000002242 embryoid body Anatomy 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 210000004498 neuroglial cell Anatomy 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000002161 motor neuron Anatomy 0.000 description 6
- 108700007229 noggin Proteins 0.000 description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000003693 Hedgehog Proteins Human genes 0.000 description 4
- 108090000031 Hedgehog Proteins Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 102000045246 noggin Human genes 0.000 description 4
- 210000004248 oligodendroglia Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 108091008747 NR2F3 Proteins 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 239000005700 Putrescine Substances 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- VIEXQFHKRAHTQS-UHFFFAOYSA-N chloroselanyl selenohypochlorite Chemical compound Cl[Se][Se]Cl VIEXQFHKRAHTQS-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 1
- -1 Bicoid Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108700026311 Drosophila En Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 101150027852 pou3f2 gene Proteins 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Insects & Arthropods (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- High Energy & Nuclear Physics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8852108P | 2008-08-13 | 2008-08-13 | |
| US61/088,521 | 2008-08-13 | ||
| PCT/JP2009/003195 WO2010018652A1 (en) | 2008-08-13 | 2009-07-08 | Agent for promoting neuronal differentiation and method therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2733775A1 true CA2733775A1 (en) | 2010-02-18 |
Family
ID=41668806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2733775A Abandoned CA2733775A1 (en) | 2008-08-13 | 2009-07-08 | Agent for promoting neuronal differentiation and method therefor |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110183912A1 (enExample) |
| EP (1) | EP2326333B1 (enExample) |
| JP (1) | JP5794693B2 (enExample) |
| AU (1) | AU2009280769B2 (enExample) |
| CA (1) | CA2733775A1 (enExample) |
| WO (1) | WO2010018652A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012112737A2 (en) * | 2011-02-16 | 2012-08-23 | The Regents Of The University Of California | Alzheimer's disease cellular model for diagnostic and therapeutic development |
| US20150104870A1 (en) * | 2012-04-27 | 2015-04-16 | Keio University | Neuronal differentiation promoter |
| US11332719B2 (en) * | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| WO2019222134A1 (en) * | 2018-05-14 | 2019-11-21 | Baylor College Of Medicine | Coup-tfii receptor inhibitors and methods using same |
| CN119384700A (zh) | 2022-04-15 | 2025-01-28 | 艾斯本神经科学公司 | 细胞分化状态的分类方法和分化细胞的相关组合物 |
| CN116162657A (zh) * | 2022-11-21 | 2023-05-26 | 中国人民解放军军事科学院军事医学研究院 | 一种促进神经干细胞增殖和向神经元分化的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999006034A1 (en) * | 1997-08-01 | 1999-02-11 | Baylor College Of Medicine | Coup-tfi directed therapies in the treatment of disease |
| US6395546B1 (en) * | 2000-02-01 | 2002-05-28 | Neurogeneration, Inc. | Generation of dopaminergic neurons from human nervous system stem cells |
| JP3660601B2 (ja) * | 2001-03-30 | 2005-06-15 | 独立行政法人科学技術振興機構 | 胚性幹細胞からの神経幹細胞、運動ニューロン及びｇａｂａ作動性ニューロンの製造法 |
| US20030232430A1 (en) * | 2001-11-26 | 2003-12-18 | Advanced Cell Technology | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| EP1651752A2 (en) * | 2003-08-05 | 2006-05-03 | Immusol Incorporated | Methods of inhibiting cancer growth by binding to nuclear receptors |
| US20070184459A1 (en) * | 2006-02-03 | 2007-08-09 | Immusol Incorporated | Methods of inhibiting cancer growth by binding to nuclear receptors |
-
2009
- 2009-07-08 CA CA2733775A patent/CA2733775A1/en not_active Abandoned
- 2009-07-08 US US13/058,621 patent/US20110183912A1/en not_active Abandoned
- 2009-07-08 AU AU2009280769A patent/AU2009280769B2/en not_active Ceased
- 2009-07-08 WO PCT/JP2009/003195 patent/WO2010018652A1/en not_active Ceased
- 2009-07-08 JP JP2011506509A patent/JP5794693B2/ja not_active Expired - Fee Related
- 2009-07-08 EP EP09806548.5A patent/EP2326333B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| JP5794693B2 (ja) | 2015-10-14 |
| EP2326333B1 (en) | 2017-05-31 |
| AU2009280769A1 (en) | 2010-02-18 |
| JP2011530484A (ja) | 2011-12-22 |
| AU2009280769B2 (en) | 2014-09-18 |
| US20110183912A1 (en) | 2011-07-28 |
| WO2010018652A1 (en) | 2010-02-18 |
| AU2009280769A2 (en) | 2011-03-31 |
| EP2326333A4 (en) | 2013-01-23 |
| EP2326333A1 (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shimazaki et al. | A role for the POU‐III transcription factor Brn‐4 in the regulation of striatal neuron precursor differentiation | |
| US8470594B2 (en) | Methods for identifying agents that affect the survival of motor neurons | |
| US9725719B2 (en) | Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis | |
| US20150299698A1 (en) | Methods for engineering non-neuronal cells into neurons and using newly engineered neurons to treat neurodegenerative diseases | |
| US20130236964A1 (en) | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders | |
| AU2009280769B2 (en) | Agent for promoting neuronal differentiation and method therefor | |
| Yoon et al. | The thrombin receptor is a critical extracellular switch controlling myelination | |
| Yan et al. | Neurotrophin-3 promotes proliferation and cholinergic neuronal differentiation of bone marrow-derived neural stem cells via notch signaling pathway | |
| Zhou et al. | Retroviral lineage analysis of fibroblast growth factor receptor signaling in FGF2 inhibition of oligodendrocyte progenitor differentiation | |
| EP2733205B1 (en) | Corticospinal upper motor neurons, methods and compositions for differentiating neural stem cells by modulating CB1 cannabinoid receptor signaling and uses thereof | |
| Zhan et al. | A DEAD‐box RNA helicase Ddx54 protein in oligodendrocytes is indispensable for myelination in the central nervous system | |
| Honnorat et al. | POP66, a paraneoplastic encephalomyelitis-related antigen, is a marker of adult oligodendrocytes | |
| WO2008071960A2 (en) | Methods of increasing neurogenesis | |
| Merrick et al. | A role for Insulin-like growth factor 2 in specification of the fast skeletal muscle fibre | |
| US20040115808A1 (en) | Enteric nervous system derived stem and progenitor cells and uses thereof | |
| KR20110090810A (ko) | 노치 신호 활성 유전자를 이용한 줄기세포의 증식 방법 | |
| Zahir et al. | Sorbitol causes preferential selection of Muller glial precursors from late retinal progenitor cells in vitro | |
| JP6194517B2 (ja) | 神経分化促進剤 | |
| JP2017057173A (ja) | Ｔｉｍ−３をターゲットとする脳損傷疾患治療用組成物及びこのスクリーニング方法 | |
| KR101206927B1 (ko) | Ｓ１００ａ９의 발현을 억제하는 ｓｈＲＮＡ를 포함하는 치매 치료용 약학 조성물 | |
| US20180327778A1 (en) | Animal models for brain inflammation and white matter degeneration | |
| Joseph | Expression of an anti-aggregant tau mutant (TauRD/ΔK280PP) is neuroprotective in organotypic hippocampal slice cultures | |
| Waterhouse | Role of Dendritic BDNF Synthesis in Adult Neurogenesis and Spine Morphogenesis | |
| AU2005202128A1 (en) | Methods, Nucleic Acid Constructs and Cells for Treating Neurodegenerative Disorders | |
| Pinzan | Modelling etiopathogenesis of the FOXG1-duplication-linked variant of West syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140605 |
|
| FZDE | Dead |
Effective date: 20160708 |